Home › Compare › BKKPF vs ABBV
BKKPF yields 4.52% · ABBV yields 3.06%● Live data
📍 BKKPF pulled ahead of the other in Year 1
Combined, BKKPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BKKPF + ABBV for your $10,000?
Bangkok Bank Public Company Limited provides various commercial banking products and services in Thailand and internationally. The company operates through Domestic Banking, International Banking, Investment Banking, and Others segments. It offers various personal banking products and services, including savings, current, fixed deposit, foreign currency, and other accounts; home and personal loans, as well as loans for pensioners; mutual funds; investments products and services, such as bonds and debentures, as well as agency services; life and non-life bancassurance products; payment, funds transfer, currency exchange and foreign instrument, and SMS services; debit, credit, and prepaid cards; and phone and Internet banking, mobile banking, ATMs, and other services. The company also provides business banking products and services comprising operating accounts; loans for SMEs, international trade, investment banking, and e-guarantee services; securities services, such as custodian, mutual fund supervisor, provident fund registrar, securities registrar, and debenture holders' representative services; personal loans for small businesses; payment, collection, and merchant services; digital banking services; and commercial cards. In addition, it offers trade finance, remittances, export and import, project, corporate finance, and financial advisory services, as well as liquidity, fund, and asset management services. Bangkok Bank Public Company Limited was founded in 1944 and is headquartered in Bangkok, Thailand.
Full BKKPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.